Sugi Predict

Sugi Predict / Compounds / SCHEMBL390902

SCHEMBL390902

SCHEMBL390902

O=S(=O)(Cl)c1sc(Cl)cc1Br

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CCR4 P51679 1/20 0.40
▸ CCKBR P32239 1/20 0.40
▸ DAO P14920 1/20 0.38
▸ KMT2A Q03164 1/20 0.35
▸ GSK3B P49841 1/20 0.34
▸ OPRD1 P41143 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ MCL1 Q07820 1/20 0.30
▸ FLT1 P17948 1/20 0.30
▸ FLT4 P35916 1/20 0.30
▸ KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7491476 0.88 CCKBR (0.38) CCR4CCKBRDAOKMT2AGSK3B
SCHEMBL1548108 0.84 CCR4 (0.41) CCR4CCKBRDAOKMT2ACA1
SCHEMBL2914947 0.81 DAO (0.41) CCR4CCKBRDAOKMT2AGSK3B
SCHEMBL6896443 0.80 OPRD1 (0.46) GSK3BOPRD1
Hydrochloric Acid SCHEMBL27779746 0.79 DAO (0.39) CCR4CCKBRDAOKMT2AGSK3B
SCHEMBL11502895 0.78 DAO (0.42) CCKBRDAOKMT2AGSK3B
SCHEMBL7502645 0.77 MCL1 (0.41) DAOPKMMCL1
SCHEMBL4606362 0.77 ALDH1A1 (0.43) OPRD1
SCHEMBL541728 0.76 RAB9A (0.43) DAOKMT2AGSK3B
Hydrochloric Acid SCHEMBL11502897 0.76 DAO (0.55) DAOKMT2AGSK3BCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 — — US disclosed
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 — — EP disclosed
US-9718809-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2017-08-01 — — US disclosed
US-20170183333-A1 DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK ARDEA BIOSCIENCES, INC. (US) 2017-06-29 — — US disclosed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 — — US disclosed
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 — — EP disclosed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 — — US disclosed
US-20140378466-A1 DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK ARDEA BIOSCIENCES (US) 2014-12-25 — — US disclosed
EP-2794009-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER Kancera AB (SE) 2014-10-29 — — EP disclosed
US-8829052-B2 Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK ARDEA BIOSCIENCES, INC. (US) 2014-09-09 — — US disclosed
US-20020119969-A1 Novel process NOVO NORDISK A/S (DK) 2002-08-29 — — US disclosed
WO-2002057252-A2 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION WYETH (US) 2002-07-25 — — WO disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 — — EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 — — EP disclosed
EP-1194430-A1 NOVEL PROCESS NOVO NORDISK A/S (DK) 2002-04-10 — — EP disclosed
WO-2001090092-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 — — WO disclosed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 — — WO disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 — — WO disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 — — WO disclosed
WO-2001002410-A1 NOVEL PROCESS NOVO NORDISK A/S (DK) 2001-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF CCR4 986/4885CCKBR 2494/4885DAO 3683/4885
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF CCR4 1036/4885CCKBR 2580/4885DAO 3556/4885
US-20170183333-A1 DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK BRAF, NRAS, MAP3K2 CCR4 4190/4885CCKBR 4411/4885DAO 2961/4885
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer NFKBIA, IL6, LITAF CCR4 1036/4885CCKBR 2580/4885DAO 3556/4885
US-20140378466-A1 DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK BRAF, NRAS, MAP3K2 CCR4 4190/4885CCKBR 4411/4885DAO 2961/4885
US-20020119969-A1 Novel process CYP3A5, CYP4F2, CYP4F12 CCR4 3947/4885CCKBR 1602/4885DAO 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.